ArticleDiscover oncology2026
A prognostic signature of ferroptosis and lipid metabolism related genes predicts survival and immunotherapy response in hepatocellular carcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC) is a common and aggressive form of cancer. There is an interplay between ferroptosis and lipid metabolism in various types of cancer. The objective of this research is to examine the functions of genes related to ferroptosis and lipid metabolism (FLMRGs) in HCC, develop prognostic models, and analyze their significance for immunotherapy and treatment response.
methodsRNA-seq data from TCGA and GEO databases were analyzed. Differential expression analysis was used to identify FLMRGs in HCC. Consensus clustering categorized patients into distinct clusters. Prognostic models were built using Cox regression and machine learning. Immune infiltration, mutation, and drug response analyses were conducted to assess the tumor microenvironment and therapeutic potential.
resultsWe identified 14 differentially expressed FLMRGs between HCC and normal samples, of which 12 genes were correlated with the prognosis of HCC patients. HCC patients were categorized into two FLMRG clusters. These clusters were associated with HCC patient survival and immune cell infiltration. We identified differentially expressed genes between the two FLMRG clusters, and prognosis-related DEGs were utilized to construct a FLMRG prognostic signature (risk score). HCC patients with a high-risk score exhibited poor prognosis. Furthermore, the risk score model was correlated with immune cell infiltration, responses to immunotherapy, and drug sensitivity in HCC patients. High-risk patients demonstrated increased expression of immune checkpoints and higher tumor mutational burden (TMB). The signature genes displayed differential expression and prognostic value in HCC.
conclusionOur study highlights the significance of FLMRGs in HCC prognosis and may provide insights for personalized immunotherapy and chemotherapy strategies, contributing to the understanding of HCC pathogenesis and treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.